June 4, 2019
Chugai Pharmaceutical filed its ALK inhibitor Alecensa (alectinib) for an additional indication of anaplastic large cell lymphoma, a rare type of non-Hodgkin’s lymphoma, on June 3, the company said the same day. The move came days after Alecensa gained orphan...read more